These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28366269)

  • 1. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2017 May; 25(10):2813. PubMed ID: 28366269
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2016 Sep; 24(18):4517. PubMed ID: 27544046
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.
    Nakajima Y; Tojo T; Morita M; Hatanaka K; Shirakami S; Tanaka A; Sasaki H; Nakai K; Mukoyoshi K; Hamaguchi H; Takahashi F; Moritomo A; Higashi Y; Inoue T
    Chem Pharm Bull (Tokyo); 2015; 63(5):341-53. PubMed ID: 25786493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].
    Wu TM; Wang DC; Xiang P; Zhang JN; Sang YX; Lin HJ; Chen J; Xie G; Song H; Zhao YL; Xie YM
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4558. PubMed ID: 27542309
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2022 Jan; 56():128501. PubMed ID: 34911648
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents" [Bioorg. Med. Chem. Lett. 27 (2017) 4471-4477].
    Cooper AB; Ciblat S; Shipps G; Levine J; Kostura M; Oza V; Constantineau-Forget L; Dery M; Grand-Maitre C; Bruneau-Latour N; Bellavance E; Patane M; Siddiqui A; Luther M
    Bioorg Med Chem Lett; 2018 Mar; 28(5):985. PubMed ID: 29433931
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys" [Bioorg. Med. Chem. 56 (2022) 116587].
    Imaizumi T; Otsubo S; Maemoto M; Kobayashi A; Komai M; Takada H; Sakaida Y; Otsubo N
    Bioorg Med Chem; 2022 Apr; 59():116678. PubMed ID: 35210135
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors" [Bioorg. Med. Chem. 40 (2021) 116186].
    Bu H; Yuan X; Wu H; Zhou J; Zhang H
    Bioorg Med Chem; 2022 Jan; 54():116578. PubMed ID: 34920926
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126931. PubMed ID: 31902709
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents" [Bioorg. Med. Chem. Lett. 27 (3) (2017) 602-606].
    Li J; Li D; Xu Y; Guo Z; Liu X; Yang H; Wu L; Wang L
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3822. PubMed ID: 30385163
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives" [Bioorg. Med. Chem. Lett. 28 (14) (2018) 2481-2484].
    Derabli C; Boualia I; Abdelwahab AB; Boulcina R; Bensouici C; Kirsch G; Debache A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3129. PubMed ID: 30119958
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Synthesis and biological activity of 2,5-diaryl-3-methylpyrimido[4,5-c]quinolin-1(2H)-one derivatives" [Bioorg. Med. Chem. 15 (2007) 2434-2440].
    Metwally K; Aly O; Aly E; Banerjee A; Ravindra R; Bane S
    Bioorg Med Chem; 2017 May; 25(9):2679. PubMed ID: 28341404
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Design, synthesis and biological evaluation of novel procaine derivatives for intravenous anesthesia" [Bioorg. Med. Chem. Lett. 60 (2022) 128587].
    Yin J; Zhao Y; He Q; Hai A; Peng Y; Zuo Z; Gao L; Song Z; Ke B
    Bioorg Med Chem Lett; 2022 Jul; 68():128765. PubMed ID: 35525630
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARĪ² agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].
    Goncalves MB; Clarke E; Jarvis CI; Kalindjian SB; Pitcher T; Grist J; Hobbs C; Carlstedt T; Jack J; Brown JT; Mills M; Mumford P; Borthwick AD; Corcoran JPT
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2440-2441. PubMed ID: 31208764
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents" [Bioorg. Med. Chem. Lett. 18 (2008) 6054-6057].
    Sekhar KVGC; Rao VS; Devambatla RKV; Kumar MMK
    Bioorg Med Chem Lett; 2017 May; 27(9):2081. PubMed ID: 28336140
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family" [Bioorg. Med. Chem. 39 (2021) 116133].
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2022 Jan; 54():116574. PubMed ID: 34922820
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3205. PubMed ID: 28551102
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents" [Bioorg. Med. Chem. 19 (2011) 5409-5419].
    Kumar A; Tripathi VD; Kumar P; Gupta LP; Akanksha ; Trivedi R; Bid H; Nayak VL; Siddiqui JA; Chakravarti B; Saxena R; Dwivedi A; Siddiquee MI; Siddiqui U; Konwar R; Chattopadhyay N
    Bioorg Med Chem; 2019 Sep; 27(17):3960-3961. PubMed ID: 31345744
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors" [Bioorg. Med. Chem. Lett. 53 (2021) 128409].
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2022 Jan; 56():128502. PubMed ID: 34906405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.